HLA Typing Market by Technology (PCR, NGS, Sanger Sequencing), Product (Instrument, Reagent), Application (Cancer research, infectious & Non infectious diseases, Transfusion therapy), End User (Hospital, Academia and Research) - Global Forecast to 2025
[185 Pages Report] The global HLA typing market is projected to reach USD 1.7 billion by 2025 from USD 1.2 billion in 2019, at a CAGR of 5.9%. Growth in the HLA typing market is mainly driven by factors such as the increasing number of HLA typing procedures conducted, technological advancements in the field of HLA typing, and increasing funding for research. However, the high costs of HLA typing products and limited reimbursements for target procedures are expected to restrain market growth in the coming years. Along with this, the significant supply-demand gap between the number of organ donors and organs required annually is expected to challenge market growth to a certain extent.
By product and service, reagents & consumables accounted for the largest market share in 2019.
On the basis of product & service, the HLA typing market has been segmented into reagents & consumables, instruments, and software & services. The reagents & consumables segment accounted for the largest share of the HLA typing market in 2019. The segment is expected to register the highest growth in the same year. Factors such as the growing application horizons of molecular assay techniques in HLA typing, increasing patient emphasis on effective and early patient profiling during organ transplantation, the growing adoption of molecular diagnostic techniques in research studies, and the rising number of target procedures across major markets are driving the growth of this segment.
Based on technology, the molecular assay technologies segment accounted for the largest share in 2019.
On the basis of technology, the HLA typing market is segmented into molecular and non-molecular assay technologies. The molecular assay technologies segment accounted for the largest share of the HLA typing market in 2019. The growth of this segment is attributed to their benefits over non-molecular assays, such as low turnaround times, high procedural efficacy, multi-sample study capabilities, and real-time sample analysis.
The diagnostic applications segment will continue to dominate the HLA typing market in 2025.
On the basis of application, the HLA typing market is segmented into diagnostic and research applications. The diagnostic applications segment dominated the HLA typing market in 2018. This is attributed to technological advancements in molecular assay techniques, the increasing adoption of molecular assay procedures for pathogen encounter detection and histocompatibility cross-matching, and the growing incidence of chronic and infectious diseases.
The commercial service providers segment accounted for the largest share of the HLA typing market in 2019.
On the basis of end user, the HLA typing market is segmented into commercial service providers, hospitals & surgical centers, and research laboratories & academic institutes. In 2019, the commercial service providers segment accounted for the largest share of the HLA typing market due to the rapid modernization and adoption of automation in HLA typing, growing outsourcing of R&D activities to said providers, and the increasing consolidation of diagnostic laboratories.
The market in the Asia Pacific is expected to grow at the highest CAGR during the forecast period.
The HLA typing market is segmented into five major regions, namely, North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. The Asia Pacific market is estimated to grow at the highest CAGR during the forecast period, primarily due to the improving healthcare infrastructure, rising awareness, improving reimbursement scenario, and the growing insurance coverage in several APAC countries.
Key Market Players
Thermo Fisher Scientific Inc. (US), Bio-Rad Laboratories, Inc. (US), F. Hoffman-La Roche Ltd. (Switzerland), QIAGEN N.V. (Netherlands), Illumina, Inc. (US), Immucor, Inc. (US), CareDx (US), Becton, Dickinson and Company (US), Hologic (US), GenDx (Netherlands), and Biofortuna (UK) are the players in this market.
Thermo Fisher Scientific (US) is one of the leading manufacturers of life science research and medical diagnostic products. The company focuses on launching technologically advanced products to maintain its leadership in the HLA typing industry. Furthermore, the company focuses on strengthening its revenue growth and brand positioning by adopting strategies such as acquisitions and expansions. Pertinent to this, Thermo Fisher Scientific acquired several companies to further enhance its presence in the market. These acquisitions enabled the company to expand and strengthen its product portfolio as well as develop innovative diagnostic technologies.
Get online access to the report on the World's First Market Intelligence Cloud
- Easy to Download Historical Data & Forecast Numbers
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
Request Sample Scope of the Report
Get online access to the report on the World's First Market Intelligence Cloud
- Easy to Download Historical Data & Forecast Numbers
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
|
Report Metric |
Details |
|
Market Size Available for Years |
20172025 |
|
Base Year Considered |
2018 |
|
Forecast Period |
20192025 |
|
Forecast Units |
Value (USD) |
|
Segments Covered |
Product and Service, Technology, Application, End User, and Region |
|
Geographies Covered |
North America, Europe, APAC, Latin America, and the Middle East & Africa |
|
Companies Covered |
Thermo Fisher Scientific Inc. (US), Bio-Rad Laboratories, Inc. (US), F. Hoffman-La Roche Ltd. (Switzerland), QIAGEN N.V. (Netherlands), Illumina, Inc. (US), Immucor, Inc. (US), CareDx (US), Becton, Dickinson and Company (US), Hologic (US), GenDx (Netherlands), and Biofortuna (UK), among others. |
This research report categorizes the HLA typing market based on product, technology, application, end user, and region.
HLA Typing Market, by Product & Service
- Reagents & consumables
- Instruments
- Software & services
HLA Typing Market, by Application
- Diagnostic applications
- Donor-recipient cross-matching
- Infectious Disease Testing
- Cancer Diagnosis & Prevention
- Transfusion Therapy
- Other Diagnostic Applications
- Research applications
HLA Typing Market, by Technology
- Molecular assay technologies
- Non-molecular assay technologies
HLA Typing Market, by End User
- Commercial service providers
- Hospitals & surgical centers
- Research laboratories & academic institutes
HLA Typing Market, by Region
- North America
- US
- Canada
- Europe
- Germany
- France
- UK
- Italy
- Spain
- RoE
- Asia Pacific
- Japan
- China
- India
- Australia
- South Korea
- RoAPAC
- Latin America
- Brazil
- Mexico
- RoLATAM
- Middle East & Africa
Key Questions Addressed by the Report:
- What are the growth opportunities related to the adoption of HLA typing products across major regions in the future?
- Which product segment will register the highest adoption rate during the forecast period?
- Emerging countries have immense opportunities for the growth and adoption of HLA typing products. Will this scenario continue in the next five years?
- Where will all the advancements in products offered by various companies take the industry in the mid- to long-term?
- Which end users are estimated to adopt HLA typing products?
- What are the new trends and advancements in the HLA typing market?
Frequently Asked Questions (FAQ):
What is the expected addressable market value of major HLA typing market products over a 5-year period?
Based on the prevailing trends and estimated market value data as of 2019, the total market value of major HLA typing products is estimated to be about USD 1.7 billion as of 2025.
Which product categories are expected to have highest growth rate in the HLA typing market?
The reagents & consumables segment accounted for the largest share of 71.8% of the HLA typing market in 2018. This segment is also projected to register the highest CAGR during the forecast period (2019-2024). Their demand growth is mainly driven by increased prevalence of related injuries (such as ACL & spinal procedures), utilization of target products among sports person for preventive care, and rising sales through off-the-shelf channel.
What are the opportunistic areas are available for new and existing players in the HLA typing market to enhance their market share?
Rising adoption of cross-matching and chimerism testing and increasing public awareness about transplantation are some of the key opportunistic areas available for the emerging as well as established players in the market.
What are the major revenue pockets in the HLA typing market currently?
North America accounted for the largest share of 45.0% (with US garnering the most of 94.3%) of the HLA typing market in 2018. This is majorly attributed to the high adoption of advanced diagnostic technologies, increasing prevalence of target diseases in the US and Canada, and technological advancements. The rising geriatric population and growing funding and support for research are other major factors driving the growth of this regional segment.
To speak to our analyst for a discussion on the above findings, click Speak to Analyst
TABLE OF CONTENTS
1 INTRODUCTION (Page No. - 19)
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 MARKET SCOPE
1.3.1 MARKETS COVERED
1.3.2 YEARS CONSIDERED FOR THE STUDY
1.4 CURRENCY USED FOR THE STUDY
1.5 MAJOR MARKET STAKEHOLDERS
2 RESEARCH METHODOLOGY (Page No. - 23)
2.1 RESEARCH DATA
2.1.1 SECONDARY DATA
2.1.1.1 Secondary sources
2.1.2 PRIMARY DATA
2.2 MARKET ESTIMATION METHODOLOGY
2.2.1 REVENUE MAPPING-BASED MARKET ESTIMATION
2.2.2 PROCEDURE-BASED MARKET ESTIMATION
2.2.3 PRIMARY RESEARCH VALIDATION
2.3 DATA TRIANGULATION
2.4 RESEARCH ASSUMPTIONS
2.5 RESEARCH LIMITATIONS
3 EXECUTIVE SUMMARY (Page No. - 32)
4 PREMIUM INSIGHTS (Page No. - 36)
4.1 HLA TYPING MARKET: MARKET OVERVIEW
4.2 GLOBAL MARKET BREAKDOWN, BY PRODUCT & SERVICE
4.3 HLA TYPING MARKET, BY TECHNOLOGY
4.4 HLA TYPING MARKET, BY APPLICATION
4.5 HLA TYPING MARKET, BY END USER
4.6 GEOGRAPHIC SNAPSHOT OF THE HLA TYPING MARKET
5 MARKET OVERVIEW (Page No. - 40)
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
5.2.1 DRIVERS
5.2.1.1 Increasing number of organ transplantation procedures
5.2.1.2 Technological advancements in the field of HLA typing
5.2.1.3 Increasing public-private funding for research
5.2.1.4 Increasing prevalence of infectious & non-infectious diseases
5.2.2 RESTRAINTS
5.2.2.1 High cost of HLA typing products
5.2.2.2 Limited reimbursements for target procedures
5.2.3 OPPORTUNITIES
5.2.3.1 Rising adoption of cross-matching and chimerism testing
5.2.3.2 Increasing public awareness about transplantation
5.2.4 CHALLENGES
5.2.4.1 Supply-demand gap between the number of organ donors and organs required annually
5.2.4.2 Dearth of skilled professionals for performing HLA typing
6 HLA TYPING MARKET, BY PRODUCT & SERVICE (Page No. - 47)
6.1 INTRODUCTION
6.2 REAGENTS & CONSUMABLES
6.2.1 EXPANDING APPLICATIONS OF MOLECULAR ASSAY TECHNIQUES LIKE PCR AND NGS IN HLA TYPING WILL AID MARKET GROWTH
6.3 INSTRUMENTS
6.3.1 TECHNOLOGICAL ADVANCEMENTS AND INCREASING AWARENESS SUPPORT THE ADOPTION OF INSTRUMENTS
6.4 SOFTWARE & SERVICES
6.4.1 AUTOMATION AND DIGITIZATION IN LAB PROCEDURES AND RISING DEMAND FOR SPECIALIZED EQUIPMENT ARE DRIVING MARKET GROWTH
7 HLA TYPING MARKET, BY TECHNOLOGY (Page No. - 51)
7.1 INTRODUCTION
7.2 MOLECULAR ASSAY TECHNOLOGIES
7.2.1 PCR-BASED MOLECULAR ASSAYS
7.2.1.1 Sequence-specific primer-PCR
7.2.1.1.1 Expanding distribution networks of key PCR manufacturers to support market growth
7.2.1.2 Sequence-specific oligonucleotide-PCR
7.2.1.2.1 High demand of SSO-PCR is due to its benefits in donor-recipient cross-matching and disease diagnosis
7.2.1.3 Real-time PCR
7.2.1.3.1 Growing end-user preference for genome-based molecular diagnostics has supported the demand for real-time PCR
7.2.1.4 Other PCR-based molecular assays
7.2.2 SEQUENCING-BASED MOLECULAR ASSAYS
7.2.2.1 Sanger sequencing
7.2.2.1.1 Rising end-user preference for low-cost and efficient DNA sequencing technology drives market growth
7.2.2.2 Next-generation sequencing
7.2.2.2.1 High scalability, low turnaround time, and high-throughput capabilities have fueled the use of NGS
7.2.2.3 Other sequencing-based molecular assays
7.3 NON-MOLECULAR ASSAY TECHNOLOGIES
7.3.1 RAPID ADOPTION OF MOLECULAR ASSAY TECHNIQUES WILL HAMPER MARKET GROWTH IN THIS SEGMENT
8 HLA TYPING MARKET, BY APPLICATION (Page No. - 66)
8.1 INTRODUCTION
8.2 DIAGNOSTIC APPLICATIONS
8.2.1 DONOR-RECIPIENT CROSS-MATCHING
8.2.1.1 Need for histocompatibility cross-matching in organ transplantation drives market growth
8.2.2 INFECTIOUS DISEASE TESTING
8.2.2.1 Growing burden of infectious diseases is likely to aid market growth
8.2.3 CANCER DIAGNOSIS & PREVENTION
8.2.3.1 Clinical evidence for the success of HLA typing in cancer diagnostics will positively affect this market
8.2.4 TRANSFUSION THERAPY
8.2.4.1 Increasing evidence for the success of HLA typing in blood transfusion is a key contributor to market growth
8.2.5 OTHER DIAGNOSTIC APPLICATIONS
8.3 RESEARCH APPLICATIONS
8.3.1 RISING FUNDING FOR RESEARCH AND EXPANDING APPLICATIONS OF HLA TYPING ARE DRIVING MARKET GROWTH
9 HLA TYPING MARKET, BY END USER (Page No. - 74)
9.1 INTRODUCTION
9.2 COMMERCIAL SERVICE PROVIDERS
9.2.1 RAPID MODERNIZATION AND AUTOMATION IN HLA TYPING TO SUPPORT MARKET GROWTH IN THIS SEGMENT
9.3 HOSPITALS & TRANSPLANT CENTERS
9.3.1 HIGH PURCHASING POWER OF HOSPITALS HAS ENSURED STRONG ADOPTION OF INSTRUMENTS, REAGENTS, AND CONSUMABLES
9.4 RESEARCH LABORATORIES & ACADEMIC INSTITUTES
9.4.1 RISING GOVERNMENT SUPPORT FOR RESEARCH RELATED TO CANCER DIAGNOSIS WILL PROPEL MARKET GROWTH
10 HLA TYPING MARKET, BY REGION (Page No. - 79)
10.1 INTRODUCTION
10.2 NORTH AMERICA
10.2.1 US
10.2.1.1 Technological advancements in the field of HLA typing will drive market growth in the US
10.2.2 CANADA
10.2.2.1 Rising incidence of cancer will support the adoption of genomic research in Canada
10.3 EUROPE
10.3.1 GERMANY
10.3.1.1 Germany accounted for the largest share of the European market
10.3.2 UK
10.3.2.1 Rising prevalence of autoimmune diseases drives market growth in the UK
10.3.3 FRANCE
10.3.3.1 Increasing organ rejection rate drives the need for HLA typing in France
10.3.4 ITALY
10.3.4.1 Italys healthcare sector has witnessed sluggish growth in recent years
10.3.5 SPAIN
10.3.5.1 Rising number of solid-organ transplantation procedures to drive market growth in Spain
10.3.6 REST OF EUROPE
10.4 ASIA PACIFIC
10.4.1 CHINA
10.4.1.1 Supportive government regulations will drive market growth in China
10.4.2 INDIA
10.4.2.1 Increasing number of transplantation procedures drives market growth in India
10.4.3 JAPAN
10.4.3.1 Limited research and exploration in the diagnostics field to limit the adoption of HLA procedures
10.4.4 AUSTRALIA
10.4.4.1 Rising prevalence of coeliac disease in Australia to support the HLA typing market
10.4.5 SOUTH KOREA
10.4.5.1 Expansion by leading market players in South Korea will support market growth
10.4.6 REST OF ASIA PACIFIC
10.5 LATIN AMERICA
10.5.1 BRAZIL
10.5.1.1 Brazil dominates the LATAM market
10.5.2 MEXICO
10.5.2.1 Rising medical tourism to support market growth in Mexico
10.5.3 REST OF LATAM
10.6 MIDDLE EAST AND AFRICA
10.6.1 MEA WILL HOLD A SMALLER SHARE AND GROW AT A LESSER RATE THAN MAJOR REGIONAL MARKETS
11 COMPETITIVE LANDSCAPE (Page No. - 125)
11.1 OVERVIEW
11.2 MARKET SHARE ANALYSIS
11.3 COMPETITIVE SCENARIO
11.3.1 KEY PRODUCT LAUNCHES AND APPROVALS
11.3.2 KEY AGREEMENTS AND COLLABORATIONS
11.3.3 KEY ACQUISITIONS
11.3.4 KEY EXPANSIONS
11.4 COMPETITIVE LEADERSHIP MAPPING
11.4.1 VISIONARY LEADERS
11.4.2 INNOVATORS
11.4.3 DYNAMIC DIFFERENTIATORS
11.4.4 EMERGING COMPANIES
12 COMPANY PROFILES (Page No. - 131)
(Business Overview, Products Offered, Recent Developments, MnM View)*
12.1 THERMO FISHER SCIENTIFIC
12.2 QIAGEN
12.3 ILLUMINA
12.4 F. HOFFMAN-LA ROCHE LIMITED
12.5 BIO-RAD LABORATORIES
12.6 BECTON, DICKINSON AND COMPANY
12.7 TBG DIAGNOSTICS
12.8 FUJIREBIO
12.9 TAKARA BIO
12.10 CAREDX
12.11 OMIXON
12.12 IMMUCOR
12.13 GENOME DIAGNOSTICS
12.14 BIOFORTUNA
12.15 CREATIVE BIOLABS
12.16 OTHER COMPANIES
12.16.1 BAG HEALTHCARE
12.16.2 HISTOGENETICS
12.16.3 PACIFIC BIOSCIENCES OF CALIFORNIA
12.16.4 BGI GENOMICS
12.16.5 KRISHGEN BIOSYSTEMS
*Business Overview, Products Offered, Recent Developments, MnM View might not be captured in case of unlisted companies.
13 APPENDIX (Page No. - 171)
13.1 DISCUSSION GUIDE
13.2 KNOWLEDGE STORE: MARKETSANDMARKETS SUBSCRIPTION PORTAL
13.3 AVAILABLE CUSTOMIZATIONS
13.4 RELATED REPORTS
13.5 AUTHOR DETAILS
LIST OF TABLES (158 Tables)
TABLE 1 PUBLIC-PRIVATE INVESTMENTS AND RESEARCH GRANTS FOR THE DEVELOPMENT OF HLA TYPING PRODUCTS, 20152018
TABLE 2 COST OF ASSAYS FOR MAJOR NGS/PCR-BASED GENOMIC TESTS IN EUROPE (AS OF 2017)
TABLE 3 HLA TYPING MARKET, BY PRODUCT & SERVICE, 20172025 (USD MILLION)
TABLE 4 HLA TYPING MARKET FOR REAGENTS & CONSUMABLES, BY REGION, 20172025 (USD MILLION)
TABLE 5 HLA TYPING MARKET FOR INSTRUMENTS, BY REGION, 20172025 (USD MILLION)
TABLE 6 HLA TYPING MARKET FOR SOFTWARE & SERVICES, BY REGION, 20172025 (USD MILLION)
TABLE 7 HLA TYPING MARKET, BY TECHNOLOGY, 20172025 (USD MILLION)
TABLE 8 HLA TYPING MARKET FOR MOLECULAR ASSAY TECHNOLOGIES, BY TYPE, 20172025 (USD MILLION)
TABLE 9 HLA TYPING MARKET FOR MOLECULAR ASSAY TECHNOLOGIES, BY PRODUCT & SERVICE, 20172025 (USD MILLION)
TABLE 10 HLA TYPING MARKET FOR MOLECULAR ASSAY TECHNOLOGIES, BY APPLICATION, 20172025 (USD MILLION)
TABLE 11 HLA TYPING MARKET FOR MOLECULAR ASSAY TECHNOLOGIES, BY END USER, 20172025 (USD MILLION)
TABLE 12 HLA TYPING MARKET FOR MOLECULAR ASSAY TECHNOLOGIES, BY REGION, 20172025 (USD MILLION)
TABLE 13 HLA TYPING MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 20172025 (USD MILLION)
TABLE 14 HLA TYPING MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY PRODUCT & SERVICE, 20172025 (USD MILLION)
TABLE 15 HLA TYPING MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY APPLICATION, 20172025 (USD MILLION)
TABLE 16 HLA TYPING MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY END USER, 20172025 (USD MILLION)
TABLE 17 HLA TYPING MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY REGION, 20172025 (USD MILLION)
TABLE 18 HLA TYPING MARKET FOR SEQUENCE-SPECIFIC PRIMER-PCR, BY REGION, 20172025 (USD MILLION)
TABLE 19 HLA TYPING MARKET FOR SEQUENCE-SPECIFIC OLIGONUCLEOTIDE-PCR, BY REGION, 20172025 (USD MILLION)
TABLE 20 HLA TYPING MARKET FOR REAL-TIME PCR, BY REGION, 20172025 (USD MILLION)
TABLE 21 HLA TYPING MARKET FOR OTHER PCR-BASED MOLECULAR ASSAYS, BY REGION, 20172025 (USD MILLION)
TABLE 22 HLA TYPING MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 20172025 (USD MILLION)
TABLE 23 HLA TYPING MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY PRODUCT & SERVICE, 20172025 (USD MILLION)
TABLE 24 HLA TYPING MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY APPLICATION, 20172025 (USD MILLION)
TABLE 25 HLA TYPING MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY END USER, 20172025 (USD MILLION)
TABLE 26 HLA TYPING MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY REGION, 20172025 (USD MILLION)
TABLE 27 HLA TYPING MARKET FOR SANGER SEQUENCING, BY REGION, 20172025 (USD MILLION)
TABLE 28 HLA TYPING MARKET FOR NEXT-GENERATION SEQUENCING, BY REGION, 20172025 (USD MILLION)
TABLE 29 HLA TYPING MARKET FOR OTHER SEQUENCING-BASED MOLECULAR ASSAYS, BY REGION, 20172025 (USD MILLION)
TABLE 30 HLA TYPING MARKET FOR NON-MOLECULAR ASSAY TECHNOLOGIES, BY PRODUCT & SERVICE, 20172025 (USD MILLION)
TABLE 31 HLA TYPING MARKET FOR NON-MOLECULAR ASSAY TECHNOLOGIES, BY APPLICATION, 20172025 (USD MILLION)
TABLE 32 HLA TYPING MARKET FOR NON-MOLECULAR ASSAY TECHNOLOGIES, BY END USER, 20172025 (USD MILLION)
TABLE 33 HLA TYPING MARKET FOR NON-MOLECULAR ASSAY TECHNOLOGIES, BY REGION, 20172025 (USD MILLION)
TABLE 34 HLA TYPING MARKET, BY APPLICATION, 20172025 (USD MILLION)
TABLE 35 HLA TYPING MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 20172025 (USD MILLION)
TABLE 36 HLA TYPING MARKET FOR DIAGNOSTIC APPLICATIONS, BY REGION, 20172025 (USD MILLION)
TABLE 37 HLA TYPING MARKET FOR DONOR-RECIPIENT CROSS-MATCHING, BY REGION, 20172025 (USD MILLION)
TABLE 38 HLA TYPING MARKET FOR INFECTIOUS DISEASE TESTING, BY REGION, 20172025 (USD MILLION)
TABLE 39 HLA TYPING MARKET FOR CANCER DIAGNOSIS & PREVENTION, BY REGION, 20172025 (USD MILLION)
TABLE 40 HLA TYPING MARKET FOR TRANSFUSION THERAPY, BY REGION, 20172025 (USD MILLION)
TABLE 41 HLA TYPING MARKET FOR OTHER DIAGNOSTIC APPLICATIONS, BY REGION, 20172025 (USD MILLION)
TABLE 42 HLA TYPING MARKET FOR RESEARCH APPLICATIONS, BY REGION, 20172025 (USD MILLION)
TABLE 43 HLA TYPING MARKET, BY END USER, 20172025 (USD MILLION)
TABLE 44 HLA TYPING MARKET FOR COMMERCIAL SERVICE PROVIDERS, BY REGION, 20172025 (USD MILLION)
TABLE 45 HLA TYPING MARKET FOR HOSPITALS & TRANSPLANT CENTERS, BY REGION, 20172025 (USD MILLION)
TABLE 46 HLA TYPING MARKET FOR RESEARCH LABORATORIES & ACADEMIC INSTITUTES, BY REGION, 20172025 (USD MILLION)
TABLE 47 HLA TYPING MARKET, BY REGION, 20172025 (USD MILLION)
TABLE 48 NORTH AMERICA: HLA TYPING MARKET, BY COUNTRY, 20172025 (USD MILLION)
TABLE 49 NORTH AMERICA: HLA TYPING MARKET, BY TECHNOLOGY, 20172025 (USD MILLION)
TABLE 50 NORTH AMERICA: HLA TYPING MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 20172025 (USD MILLION)
TABLE 51 NORTH AMERICA: HLA TYPING MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 20172025 (USD MILLION)
TABLE 52 NORTH AMERICA: HLA TYPING MARKET, BY PRODUCT & SERVICE, 20172025 (USD MILLION)
TABLE 53 NORTH AMERICA: HLA TYPING MARKET, BY APPLICATION, 20172025 (USD MILLION)
TABLE 54 NORTH AMERICA: HLA TYPING MARKET, BY END USER, 20172025 (USD MILLION)
TABLE 55 SOLID-ORGAN TRANSPLANTATIONS PERFORMED IN THE US, BY TYPE, 20172018
TABLE 56 TARGET DISEASES INCIDENCE IN THE US, BY TYPE, 2018
TABLE 57 NEW CANCER CASES IN THE US, BY ORGAN, 2017
TABLE 58 US: HLA TYPING MARKET, BY TECHNOLOGY, 20172025 (USD MILLION)
TABLE 59 US: HLA TYPING MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 20172025 (USD MILLION)
TABLE 60 US: HLA TYPING MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 20172025 (USD MILLION)
TABLE 61 SOLID-ORGAN TRANSPLANTATIONS PERFORMED IN CANADA, BY TYPE, 20172018
TABLE 62 TARGET DISEASE INCIDENCE IN CANADA, 2017
TABLE 63 NEW CANCER CASES IN CANADA, BY ORGAN, 2018
TABLE 64 CANADA: HLA TYPING MARKET, BY TECHNOLOGY, 20172025 (USD MILLION)
TABLE 65 CANADA: HLA TYPING MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 20172025 (USD MILLION)
TABLE 66 CANADA: HLA TYPING MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 20172025 (USD MILLION)
TABLE 67 EUROPE: HLA TYPING MARKET, BY COUNTRY, 20172025 (USD MILLION)
TABLE 68 EUROPE: HLA TYPING MARKET, BY TECHNOLOGY, 20172025 (USD MILLION)
TABLE 69 EUROPE: HLA TYPING MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 20172025 (USD MILLION)
TABLE 70 EUROPE: HLA TYPING MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 20172025 (USD MILLION)
TABLE 71 EUROPE: HLA TYPING MARKET, BY PRODUCT & SERVICE, 20172025 (USD MILLION)
TABLE 72 EUROPE: HLA TYPING MARKET, BY APPLICATION, 20172025 (USD MILLION)
TABLE 73 EUROPE: HLA TYPING MARKET, BY END USER, 20172025 (USD MILLION)
TABLE 74 SOLID-ORGAN TRANSPLANTATIONS PERFORMED IN GERMANY, BY TYPE, 20172018
TABLE 75 TARGET DISEASE INCIDENCE IN GERMANY, 2017
TABLE 76 NEW CANCER CASES IN GERMANY, BY ORGAN, 2017
TABLE 77 GERMANY: HLA TYPING MARKET, BY TECHNOLOGY, 20172025 (USD MILLION)
TABLE 78 GERMANY: HLA TYPING MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 20172025 (USD MILLION)
TABLE 79 GERMANY: HLA TYPING MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 20172025 (USD MILLION)
TABLE 80 SOLID-ORGAN TRANSPLANTATIONS PERFORMED IN THE UK, BY TYPE, 20172018
TABLE 81 TARGET DISEASE INCIDENCE IN THE UK, 2017
TABLE 82 NEW CANCER CASES IN THE UK, BY ORGAN, 2018
TABLE 83 UK: HLA TYPING MARKET, BY TECHNOLOGY, 20172025 (USD MILLION)
TABLE 84 UK: HLA TYPING MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 20172025 (USD MILLION)
TABLE 85 UK: HLA TYPING MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 20172025 (USD MILLION)
TABLE 86 SOLID-ORGAN TRANSPLANTATIONS PERFORMED IN FRANCE, BY TYPE, 20172018
TABLE 87 NEW CANCER CASES IN FRANCE, BY ORGAN, 2018
TABLE 88 FRANCE: HLA TYPING MARKET, BY TECHNOLOGY, 20172025 (USD MILLION)
TABLE 89 FRANCE: HLA TYPING MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 20172025 (USD MILLION)
TABLE 90 FRANCE: HLA TYPING MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 20172025 (USD MILLION)
TABLE 91 ITALY: HLA TYPING MARKET, BY TECHNOLOGY, 20172025 (USD MILLION)
TABLE 92 ITALY: HLA TYPING MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 20172025 (USD MILLION)
TABLE 93 ITALY: HLA TYPING MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 20172025 (USD MILLION)
TABLE 94 SPAIN: HLA TYPING MARKET, BY TECHNOLOGY, 20172025 (USD MILLION)
TABLE 95 SPAIN: HLA TYPING MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 20172025 (USD MILLION)
TABLE 96 SPAIN: HLA TYPING MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 20172025 (USD MILLION)
TABLE 97 ROE: HLA TYPING MARKET, BY TECHNOLOGY, 20172025 (USD MILLION)
TABLE 98 ROE: HLA TYPING MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 20172025 (USD MILLION)
TABLE 99 ROE: HLA TYPING MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 20172025 (USD MILLION)
TABLE 100 ASIA PACIFIC: HLA TYPING MARKET, BY COUNTRY, 20172025 (USD MILLION)
TABLE 101 ASIA PACIFIC: HLA TYPING MARKET, BY TECHNOLOGY, 20172025 (USD MILLION)
TABLE 102 ASIA PACIFIC: HLA TYPING MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 20172025 (USD MILLION)
TABLE 103 ASIA PACIFIC: HLA TYPING MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 20172025 (USD MILLION)
TABLE 104 ASIA PACIFIC: HLA TYPING MARKET, BY PRODUCT & SERVICE, 20172025 (USD MILLION)
TABLE 105 ASIA PACIFIC: HLA TYPING MARKET, BY APPLICATION, 20172025 (USD MILLION)
TABLE 106 ASIA PACIFIC: HLA TYPING MARKET, BY END USER, 20172025 (USD MILLION)
TABLE 107 SOLID-ORGAN TRANSPLANTATIONS PERFORMED IN CHINA, BY TYPE, 20172018
TABLE 108 NEW CANCER CASES IN CHINA, BY ORGAN, 2018
TABLE 109 CHINA: HLA TYPING MARKET, BY TECHNOLOGY, 20172025 (USD MILLION)
TABLE 110 CHINA: HLA TYPING MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 20172025 (USD MILLION)
TABLE 111 CHINA: HLA TYPING MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 20172025 (USD MILLION)
TABLE 112 SOLID-ORGAN TRANSPLANTATIONS PERFORMED IN INDIA, BY TYPE, 20172018
TABLE 113 NEW CANCER CASES IN INDIA, BY ORGAN, 2018
TABLE 114 INDIA: HLA TYPING MARKET, BY TECHNOLOGY, 20172025 (USD MILLION)
TABLE 115 INDIA: HLA TYPING MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 20172025 (USD MILLION)
TABLE 116 INDIA: HLA TYPING MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 20172025 (USD MILLION)
TABLE 117 SOLID-ORGAN TRANSPLANTATIONS PERFORMED IN JAPAN, BY TYPE, 20172018
TABLE 118 NEW CANCER CASES IN JAPAN, BY ORGAN, 2018
TABLE 119 JAPAN: HLA TYPING MARKET, BY TECHNOLOGY, 20172025 (USD MILLION)
TABLE 120 JAPAN: HLA TYPING MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 20172025 (USD MILLION)
TABLE 121 JAPAN: HLA TYPING MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 20172025 (USD MILLION)
TABLE 122 SOLID-ORGAN TRANSPLANTATIONS PERFORMED IN AUSTRALIA, BY TYPE, 20172018
TABLE 123 NEW CANCER CASES IN AUSTRALIA, BY ORGAN, 2018
TABLE 124 AUSTRALIA: HLA TYPING MARKET, BY TECHNOLOGY, 20172025 (USD MILLION)
TABLE 125 AUSTRALIA: HLA TYPING MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 20172025 (USD MILLION)
TABLE 126 AUSTRALIA: HLA TYPING MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 20172025 (USD MILLION)
TABLE 127 SOUTH KOREA: HLA TYPING MARKET, BY TECHNOLOGY, 20172025 (USD MILLION)
TABLE 128 SOUTH KOREA: HLA TYPING MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 20172025 (USD MILLION)
TABLE 129 SOUTH KOREA: HLA TYPING MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 20172025 (USD MILLION)
TABLE 130 ROAPAC: HLA TYPING MARKET, BY TECHNOLOGY, 20172025 (USD MILLION)
TABLE 131 ROAPAC: HLA TYPING MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 20172025 (USD MILLION)
TABLE 132 ROAPAC: HLA TYPING MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 20172025 (USD MILLION)
TABLE 133 LATAM: HLA TYPING MARKET, BY COUNTRY, 20172025 (USD MILLION)
TABLE 134 LATAM: HLA TYPING MARKET, BY TECHNOLOGY, 20172025 (USD MILLION)
TABLE 135 LATAM: HLA TYPING MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 20172025 (USD MILLION)
TABLE 136 LATAM: HLA TYPING MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 20172025 (USD MILLION)
TABLE 137 LATAM: HLA TYPING MARKET, BY PRODUCT & SERVICE, 20172025 (USD MILLION)
TABLE 138 LATAM: HLA TYPING MARKET, BY APPLICATION, 20172025 (USD MILLION)
TABLE 139 LATAM: HLA TYPING MARKET, BY END USER, 20172025 (USD MILLION)
TABLE 140 SOLID-ORGAN TRANSPLANTATIONS PERFORMED IN BRAZIL, BY TYPE, 20172018
TABLE 141 NEW CANCER CASES IN BRAZIL, BY ORGAN, 2018
TABLE 142 BRAZIL: HLA TYPING MARKET, BY TECHNOLOGY, 20172025 (USD MILLION)
TABLE 143 BRAZIL: HLA TYPING MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 20172025 (USD MILLION)
TABLE 144 BRAZIL: HLA TYPING MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 20172025 (USD MILLION)
TABLE 145 SOLID-ORGAN TRANSPLANTATIONS PERFORMED IN MEXICO, BY TYPE, 20172018
TABLE 146 NEW CANCER CASES IN MEXICO, BY ORGAN, 2018
TABLE 147 MEXICO: HLA TYPING MARKET, BY TECHNOLOGY, 20172025 (USD MILLION)
TABLE 148 MEXICO: HLA TYPING MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 20172025 (USD MILLION)
TABLE 149 MEXICO: HLA TYPING MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 20172025 (USD MILLION)
TABLE 150 ROLATAM: HLA TYPING MARKET, BY TECHNOLOGY, 20172025 (USD MILLION)
TABLE 151 ROLATAM: HLA TYPING MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 20172025 (USD MILLION)
TABLE 152 ROLATAM: HLA TYPING MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 20172025 (USD MILLION)
TABLE 153 MEA: HLA TYPING MARKET, BY TECHNOLOGY, 20172025 (USD MILLION)
TABLE 154 MEA: HLA TYPING MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 20172025 (USD MILLION)
TABLE 155 MEA: HLA TYPING MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 20172025 (USD MILLION)
TABLE 156 MEA: HLA TYPING MARKET, BY PRODUCT & SERVICE, 20172025 (USD MILLION)
TABLE 157 MEA: HLA TYPING MARKET, BY APPLICATION, 20172025 (USD MILLION)
TABLE 158 MEA: HLA TYPING MARKET, BY END USER, 20172025 (USD MILLION)
LIST OF FIGURES (33 Figures)
FIGURE 1 RESEARCH DESIGN
FIGURE 2 BREAKDOWN OF PRIMARIES: GLOBAL HLA TYPING MARKET
FIGURE 3 RESEARCH METHODOLOGY: HYPOTHESIS BUILDING
FIGURE 4 MARKET SIZE ESTIMATION: HLA TYPING MARKET
FIGURE 5 DATA TRIANGULATION METHODOLOGY
FIGURE 6 HLA TYPING MARKET SHARE, BY PRODUCT, 2019 VS. 2025 (USD MILLION)
FIGURE 7 HLA TYPING MARKET SHARE, BY APPLICATION, 2019 VS. 2025
FIGURE 8 HLA TYPING MARKET, BY TECHNOLOGY, 20192025 (USD MILLION)
FIGURE 9 HLA TYPING MARKET, BY END USER
FIGURE 10 HLA TYPING MARKET, BY REGION: GEOGRAPHICAL SNAPSHOT
FIGURE 11 INCREASING NUMBER OF ORGAN TRANSPLANTATION PROCEDURES ACROSS THE GLOBE IS SUPPORTING THE GROWTH OF THE MARKET
FIGURE 12 REAGENTS & CONSUMABLES HELD THE LARGEST SHARE OF THE MARKET
FIGURE 13 MOLECULAR ASSAY TECHNOLOGIES SEGMENT TO HOLD LARGEST SHARE OF THE GLOBAL MARKET
FIGURE 14 DIAGNOSTIC APPLICATIONS HOLD THE MAJOR SHARE OF THE MARKET, BY APPLICATION
FIGURE 15 COMMERCIAL SERVICE PROVIDERS SEGMENT WILL REGISTER THE HIGHEST CAGR
FIGURE 16 CHINA TO REGISTER THE HIGHEST CAGR DURING THE FORECAST PERIOD
FIGURE 17 HLA TYPING MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
FIGURE 18 NORTH AMERICA: HLA TYPING MARKET SNAPSHOT
FIGURE 19 ASIA PACIFIC: HLA TYPING MARKET SNAPSHOT
FIGURE 20 PRODUCT LAUNCHES AND ENHANCEMENTS WERE THE KEY GROWTH STRATEGIES ADOPTED BY MARKET PLAYERS FROM 2016 TO 2019
FIGURE 21 THERMO FISHER SCIENTIFIC DOMINATES THE GLOBAL HLA TYPING MARKET, AS OF 2019
FIGURE 22 HLA TYPING MARKET (GLOBAL): COMPETITIVE LEADERSHIP MAPPING, 2019
FIGURE 23 THERMO FISHER SCIENTIFIC: COMPANY SNAPSHOT (2018)
FIGURE 24 QIAGEN: COMPANY SNAPSHOT (2018)
FIGURE 25 ILLUMINA: COMPANY SNAPSHOT (2019)
FIGURE 26 F. HOFFMAN-LA ROCHE LIMITED: COMPANY SNAPSHOT (2018)
FIGURE 27 BIO-RAD LABORATORIES: COMPANY SNAPSHOT (2018)
FIGURE 28 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2018)
FIGURE 29 TBG DIAGNOSTICS LIMITED: COMPANY SNAPSHOT (2018)
FIGURE 30 FUJIREBIO: COMPANY SNAPSHOT (2016)
FIGURE 31 TAKARA: COMPANY SNAPSHOT (2019)
FIGURE 32 CAREDX: COMPANY SNAPSHOT (2018)
FIGURE 33 IMMUCOR: COMPANY SNAPSHOT (2016)
The study involved four major activities in estimating the current size of the HLA typing market. Exhaustive secondary research was done to collect information on the market and its different subsegments. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the complete market size. Thereafter, market breakdown and data triangulation procedures were used to estimate the size of the segments and subsegments.
Secondary Research
In the secondary research process, various secondary sources such as annual reports, press releases, and investor presentations of companies, white papers, certified publications, articles by recognized authors, gold-standard and silver-standard websites, regulatory bodies, and databases (such as D&B Hoovers, Bloomberg Businessweek, and Factiva) were referred to in order to identify and collect information for this study.
Primary Research
The HLA typing market comprises several stakeholders, such as manufacturers of HLA typing, suppliers, healthcare institutions (hospitals and outpatient clinics), and research institutions. Various primary sources from both the supply and demand sides of the market were interviewed to obtain qualitative and quantitative information. The following diagram depicts the breakdown of primary respondents:
To know about the assumptions considered for the study, download the pdf brochure
Market Size Estimation
Both top-down and bottom-up approaches were used to estimate and validate the total size of the HLA typing market. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:
- The key players in the industry and markets have been identified through extensive secondary research.
- The industrys supply chain and market size, in terms of value, have been determined through primary and secondary research processes.
- All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources.
Data Triangulation
After arriving at the overall market sizeusing the market size estimation processes as explained abovethe market was split into several segments and subsegments. In order to complete the overall market engineering process and arrive at the exact statistics of each market segment and subsegment, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides in the HLA typing market.
Report Objectives
- To define, describe, and forecast the HLA typing market on the basis of product and service, technology, application, end user, and region
- To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
- To strategically analyze micromarkets with respect to individual growth trends, prospects, and contributions to the total market
- To analyze the opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
- To forecast the revenue of market segments with respect to five major regions, namely, North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa
- To strategically profile the key players and comprehensively analyze their market shares and core competencies
- To track and analyze competitive developments such as product launches and approvals, agreements, partnerships, collaborations, acquisitions, and R&D activities in the HLA typing market
Available Customizations
With the given market data, MarketsandMarkets offers customizations as per the companys specific needs. The following customization options are available for the HLA typing market.
Product Analysis
- Product matrix, which gives a detailed comparison of the product portfolios of the top five companies
Company Information
- Detailed analysis and profiling of additional market players (up to 5)
- Triangulate with your Own Data
- Get Data as per your Format and Definition
- Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
- Any level of Personalization
- What are the Known and Unknown Adjacencies Impacting the HLA Typing Market
- What will your New Revenue Sources be?
- Who will be your Top Customer; what will make them switch?
- Defend your Market Share or Win Competitors
- Get a Scorecard for Target Partners
Growth opportunities and latent adjacency in HLA Typing Market